The Therapeutic Horizon for Primary Sclerosing Cholangitis

Dr Bilal Bobat, MBChB, FCP(SA), Cert Gastro (SA)

Head of Hepatology · University of the Witwatersrand · South Afric

About This Conference

Primary Sclerosing Cholangitis is a chronic, progressive, fibro-inflammatory condition with no current effective treatment. This may be about to change with a number of new therapeutics on the horizon. This presentation will explore some of these agents.

About the Speaker

Bilal Bobat is a Gastroenterologist and Transplant Hepatologist at the Liver Unit at Wits Donald Gordon Medical Centre. He is affiliated with the University of the Witwatersrand, Department of Internal Medicine, as a lecturer. He has a research interest in autoimmune liver diseases, specifically Primary Sclerosing Cholangitis, which is the focus of his PhD. As part of this project, he is establishing an autoimmune liver disease biobank to support further research in South Africa. Dr Bobat is a regional committee member of the International Association for the Study of the Liver (IASL) and is the regional lead for the THINK collaborative— a global transplant hepatology network. He is also affiliated with several autoimmune liver groups, including the International PSC Study Group, the International Autoimmune Hepatitis Group and the Global PBC Study Groups. Locally, he has served on the executive of the South African Gastroenterology Society (SAGES) and is a trustee of the Gastroenterology and Hepatology Foundation of Sub-Saharan Africa, an organisation focused on training and improving the quality of gastroenterology and hepatology care in the region.